HTG Molecular Diagnostics Sets Share Price Range on Planned IPO | GenomeWeb

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics today set a price range of between $13 and $15 per share on its planned initial public offering, which could bring in up to $51.4 million in net proceeds, according to a document filed with the US Securities and Exchange Commission.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.